This research uncovers novel sorbicillinoids and their effects on inflammation in cultured cells, suggesting potential therapeutic uses.
Aspersorbiciols A and B, two hybrid sorbicillinoids, were obtained from marine fungus Aspergillus sp. GXIMD02072. Their structures were elucidated by spectroscopic analyses, quantum chemical calculations, and X-ray diffraction. Structurally, aspersorbiciols A and B represented the first reported instances of sorbicillinoids incorporating a 2,6-dioxa-pentacyclo-[10.4.0.0⁴,⁸.0⁴,¹⁶.0⁸,¹³]-hexadecane cage-like skeleton. Aspersorbiciols A and B suppressed lipopolysaccharide-induced NF-κB luciferase activities and the receptor activator of NF-κB ligand-induced osteoclastogenesis.
No takes yet. Share an insight, caveat, or question.
Teng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: